SCHEMBL17016305

SCHEMBL17016305

c1ccc(-c2ccc3c4ccc(-c5ccc(-c6ccc7c(c6)c6ccc8ccn(-c9ccccc9)c8c6n7-c6ccccc6)cc5)cc4c4ccccc4c3c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ATM Q13315 1/20 0.34
KDR P35968 1/20 0.33
HTR6 P50406 3/20 0.33
PTGER4 P35408 1/20 0.32
KMT2A Q03164 4/20 0.32
MEN1 O00255 3/20 0.32
MAPT P10636 2/20 0.32
MAOB P27338 1/20 0.32
HSP90AA1 P07900 1/20 0.32
NR3C1 P04150 1/20 0.32
TSPO P30536 1/20 0.31
PLA2G4A P47712 1/20 0.31
IL1R1 P14778 1/20 0.31
LCK P06239 1/20 0.31
KIT P10721 1/20 0.31
SRC P12931 1/20 0.31
GAA P10253 1/20 0.30
NR4A2 P43354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17016310 1.00 L3MBTL1 (0.34) L3MBTL1KDM4EATMKDRHTR6
SCHEMBL17016311 0.99 KDM4E (0.35) L3MBTL1KDM4EATMKDRHTR6
SCHEMBL17016307 0.98 KDM4E (0.33) L3MBTL1KDM4EATMKDRHTR6
SCHEMBL17016302 0.97 KDM4E (0.36) L3MBTL1KDM4EATMKDRPTGER4
SCHEMBL17016306 0.96 KDM4E (0.33) L3MBTL1KDM4EATMKDRPTGER4
SCHEMBL15632012 0.95 NR3C1 (0.35) L3MBTL1KDM4EATMKDRHTR6
SCHEMBL17015334 0.94 L3MBTL1 (0.40) L3MBTL1KDM4EATMHTR6PTGER4
SCHEMBL17016207 0.94 L3MBTL1 (0.40) L3MBTL1KDM4EATMHTR6PTGER4
SCHEMBL17016261 0.93 L3MBTL1 (0.42) L3MBTL1KDM4EATMKDRHTR6
SCHEMBL17015386 0.93 L3MBTL1 (0.42) L3MBTL1KDM4EATMKDRHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 L3MBTL1 533/4885KDM4E 1286/4885ATM 3623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.